Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
- ASKA Shoots for Group Annual Sales of 70 Billion Yen in Five Years
March 29, 2016
- Asian PII Study Launched for Solasia’s PTCL Treatment: Meiji Seika Pharma
March 29, 2016
- Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
- IP High Court Rules in Favor of Chugai in Oxarol Patent Suit
March 28, 2016
- Lilly Joins Hands with NCC on Biomarkers for Advanced Gastric Cancer
March 28, 2016
- Global PIII for Xtandi Launched for Hormone Sensitive Prostate Cancer: Astellas
March 28, 2016
- Takashi Nakamura to Be Promoted to President of Qol
March 25, 2016
- Public Knowledge-Based Application Filed for Colchicine for Familial Mediterranean Fever
March 25, 2016
- MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
- Lilly Japan Logs 236 Billion Yen in 2015, Set to Further Boost Sales Force from 2,000
March 25, 2016
- Sosei Group Taps GSK Veteran Peter Bains as Next CEO
March 24, 2016
- Eisai Withdraws Japan NDA for Ultra-High Dose Mecobalamin for ALS
March 24, 2016
- Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
March 24, 2016
- Eisai to Return US Rights to Helsinn’s Antiemetic Akynzeo
March 23, 2016
- Valixa Filed for Prevention of CMV Disease in Organ Transplants: Mitsubishi Tanabe
March 23, 2016
- Romosozumab Yields Positive PIII Data in Male Osteoporosis: Amgen Astellas
March 23, 2016
- Higher Remission Rates in TNF Blocker-Naïve Patients Observed in Long-Term Vedolizumab Treatment
March 23, 2016
- Santen to Form JV with China’s Kerui for Generic Eye Drugs
March 23, 2016
- Opdivo Filed for Hodgkin’s Lymphoma in Japan
March 22, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…